Fennec Pharmaceuticals (FENC) Share-based Compensation (2010 - 2026)
Fennec Pharmaceuticals' (FENC) quarterly Share-based Compensation came in at $6.9 million in Q4 2025, up 282.72% YoY from $1.8 million in Q4 2024, and up 13644.0% on a QoQ basis from $50000.0 in Q3 2025.
Fennec Pharmaceuticals (FENC) Share-based Compensation (2010 - 2026) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 16 years of Share-based Compensation data on file, last reported at $6.9 million in Q4 2025.
- Quarterly Share-based Compensation rose 282.72% year-over-year to $6.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.0 million (up 3896.02% YoY) and the FY2025 annual result came in at $7.0 million, up 40.1% from the prior year.
- Share-based Compensation grew to $6.9 million in Q4 2025, from $50000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $6.9 million in Q4 2025 to a low of -$3.8 million in Q4 2024.
- A 5-year average of $667210.5 and a median of $798000.0 in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation soared 7165.71% — and 2024, when it tumbled 538.86%.
- Tracing FENC's Share-based Compensation over 5 years: stood at -$2.6 million in 2021, then jumped by 98.71% to -$33000.0 in 2022, then jumped by 2696.97% to $857000.0 in 2023, then plunged by 538.86% to -$3.8 million in 2024, then jumped by 282.72% to $6.9 million in 2025.
- The last three Share-based Compensation figures came in at $6.9 million (Q4 2025), $50000.0 (Q3 2025), and -$687000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Fennec Pharmaceuticals | 410.60 Mn | 369.35 Mn | 17.15 Mn | 1.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.71 Mn |
| Jun 30, 2026 | 1.71 Mn |
| Dec 31, 2025 | 6.87 Mn |
| Dec 31, 2025 | 6.87 Mn |
| Sep 30, 2025 | 50,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | -687,000.00 |
| Jun 30, 2025 | -687,000.00 |
| Mar 31, 2025 | 798,000.00 |
| Mar 31, 2025 | 798,000.00 |
| Dec 31, 2024 | -3.76 Mn |
| Dec 31, 2024 | -3.76 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Jun 30, 2024 | 2.10 Mn |
| Jun 30, 2024 | 2.10 Mn |
| Mar 31, 2024 | 19,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 857,000.00 |
| Dec 31, 2023 | 857,000.00 |